Initial acute myeloid leukemia
Conditions
Interventions
None listed
Sponsors
Children's Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Patients or their guardians voluntarily sign the informed consent and are expected to complete the follow-up examination and treatment of the research procedure; 2. According to the MICM type, the participants meet the diagnosis of de novo AML; 3. The organ function is good and meets the following laboratory indicators: direct bilirubin = 60 mL/min/1.73m2; left ventricular ejection fraction (LVEF) >= 45%, or shortened fraction >= 25%; 4. Patients must be between 1 and 18 years old, willing to receive treatment, or within 3 years after completion of treatment; 5. For patients > 16 years old, Karnofsky physical status >= 50 points; for patients <= 16 years old, Lansky functional status is not less than 50 points.
Exclusion criteria
Exclusion criteria: 1. Known to have allergic reactions to any ingredients used in the treatment of this study; 2. Patients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia or bone marrow failure syndrome are not eligible; 3. Uncontrollable systemic infection; 4. Patients with gastrointestinal dysfunction or gastrointestinal diseases are not included in this study because they may affect the absorption of venetoclax.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| dose limiting toxicity; | — |
Secondary
| Measure | Time frame |
|---|---|
| complete remission rate;partial response rate;Event-free survival;overall survival;Cumulative recurrence rate; | — |
Countries
China
Contacts
Public ContactHu Shaoyan
Children's Hospital of Soochow University
Outcome results
None listed